Articles: chronic.
-
Physiology/PFTs/Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Spirometry is recommended for the diagnosis of asthma and Chronic Obstructive Pulmonary Disease (COPD) in international guidelines and it may be useful for distinguishing asthma from COPD. Typically, the only data required for clinical decision making are the Forced Expiratory Volume in one second (FEV1) and the Forced Vital Capacity (FVC). Limitations of SIA promoted for adoption in primary care have been described [Can Fam Physician October 2011 57:1148-1152, 1153-1156.] This study examines how different SIA (one and two) may influence decision making among primary care physicians. ⋯ The following authors have nothing to disclose: Xiao Ou He, Anthony D'UrzoNo Product/Research Disclosure Information.
-
Observational Study
Patient predictors of dexmedetomidine effectiveness for sedation in intensive care units.
Dexmedetomidine, a selective α2-adrenergic receptor agonist, is increasingly used as a sedative in intensive care despite variations in patients' responses. ⋯ Effective sedation with dexmedetomidine is variable.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Adherence to treatment is an important and critical issue in patients with COPD. The purpose of this study is to examine psychological dimensions and to describe the psychological profile of stable COPD patients who comply and of those who do not comply with treatment strategies. ⋯ The following authors have nothing to disclose: Epameinondas Kosmas, Athanassios Tselebis, Dionissios Bratis, Silvia Dumitru, Elpida Theodorakopoulou, Maria Harikiopoulou, Konstantinos Velentzas, Petros Bakakos, Nachman Alchanatis, Nikolaos KoulourisNo Product/Research Disclosure Information.
-
COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Background: Chronic obstructive pulmonary disease (COPD) is a growing global epidemic especially in the developing world. It is increasingly being recognized that COPD is associated with various important comorbidities like cardiovascular diseases, osteoporosis, diabetes mellitus and metabolic syndrome. The mechanism linking COPD to systemic manifestations and comorbidities is not yet certain, but a potential mechanism to be systemic inflammation. Aim & objective: To determine the frequency of coexisting metabolic syndrome and to study the status of systemic inflammation in patients of COPD in ethnic Kashmiri population of India in view of high prevalence of COPD in them. ⋯ The following authors have nothing to disclose: Sonaullah ShahNo Product/Research Disclosure Information.
-
ILD Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Amyloidosis is the abnormal formation of proteins, amyloid fibrins. It is characterised by extracellular deposition in various organs. Pulmonary amyloidosis is rare and can present in the forms of laryngeal, tracheobronchial, pulmonary and mediastinal lymph node disease (1). We present a case of nodular pulmonary amyloidosis in a patient with MCTD. ⋯ Pulmonary amyloidosis is a rare complication of MCTD. Though radiological features can be distinguishing, tissue diagnosis is still the gold standard.Reference #1: Rajagola S, Singh N, Gupta K et al. Pulmonary amyloidosis in Sjogren's Syndrome: A case report and a systemic review of the literature. Respirology (2010) 15, 860-868Reference #2: Ito I, Nagai S, Kitaichi M et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am. J. Respir. Crit. Care Med. 2005; 171: 632-8.Reference #3: Aylwin AC, Gishen P, Copley SJ. Imaging appearance of thoracic amyloidosis. J Thorac Imaging 2005;20(1):41-46DISCLOSURE: The following authors have nothing to disclose: Chuen Peng Lee, Ser Hon Puah, Wenyuan Sim, Mark Tien, Jessica Pau, Grace Tan, Ruth ChangNo Product/Research Disclosure Information.